The glutaredoxin gene GLRX plays an important role in the immune response of gliomas and may also serve as a prognostic indicator due to its suppressive effects on T-cell response.
Why this matters
Gliomas are mainly characterised by high rates of recurrence and poor survival outcomes, despite aggressive treatment.
Novel therapeutic targets and/or molecular-targeted drugs may hold promise in improving the prognosis of patients with gliomas.
Glutaredoxin, which is encoded by the GLRX gene, performs various biological functions in cancer, but it has not been studied in the context of glioma.